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Native tissue-like L-type voltage-dependent calcium channels (L-VDCC’s) were expressed by in vitro transcribed cRNA injection of rat aorta or 
rabbit cardiac a, subunit into Xenopu.s Iucvis oocytcs. Co-injection of VSM-a, with the cloned skeletal mus&@ubunit (SK-/Y) of the L-type VDCC 
significantly increased the expressed peak currem amplitude without significant changes in kinetics. Similar results were obtained by co-injection 
of cardiac a, (DSHT-a,) the cloned skeletal c+subunit (SK-a:) or with SK-B. The oocytes co-expressing cRNA’s retained L-type VDCC 
pharmacology. 
Voltage-dependent calcium channel; Tissue-specific subunit; Co-expression: XWO,W laws oocytc 
1. INTRODUCTION 
Vascular smooth muscle (VSM) is the primary 
therapeutic target of the class of compounds known as 
the calcium antagonists, which are used to treat hyper- 
tension and angina pectoris. The drugs include the 1,4- 
dihydropyridines (DHP’s), phenylalkylamines and ben- 
zothiazepines, which selectively bind to L-type voltage- 
dependent calcium channels (VDCC’s) and produce an 
inhibition of calcium influx [I]. The L-type VDCC’s 
located in VSM bossess the highest affinity of any tissue 
for the calcium antagonists and are responsible for the 
potent vasodilatory effects seen by these agents [2,3]. 
rabbit cardiac and airway smooth VDCC, but with spe- 
cific cytoplasmic differences. It appears that these two 
channels may arise from alternative splicing of the same 
gene [14,15]. 
In the present study, we have functionally expressed 
the aortic and cardiac VDCC’s by the injection of 
cRNA’s synthesized from the rat aortic and rabbit 
cardiac a,-cDNA’s into Xrnop~~ oocytes. In addition to 
the expressed VDCC activity, which we find to be sensi- 
tive to both calcium agonists and antagonists, the co- 
injection of cRNA’s derived from the cloned rabbit skel- 
etal muscle a2 [9] and /?-subunit [161 cDNA’s stimulates 
the al-directed calcium current. 
DHP-sensitive VDCC’s have been characterized by 
biochemical and molecular biological techniques. The 
rabbit skeletal muscle VDCC exists as a pentameric 
macromolecule consisting of the cc,, a,-& p and y poly- 
peptide subunits [4-61. The a,-subunit is a large hydro- 
phobic polypeptide which is now recognized as both the 
channel-forming component as well as the specific 
calcium antagonist receptor [7]. Several groups, includ- 
ing this laboratory, have cloned full-length L-type aI- 
subunits from various sources including rabbit skeletal 
[8,9], carp skeletal muscle’ [lo], cardiac [11,12] and 
airway smooth [13] muscles. We have recently reported 
the cloning of a VSM a,-DNA isolated from rat aorta 
(VSM-cz,) [14]. This aortic cDNA is homologous to the 
2. MATERIALS AND METHODS 
2. I. In vitro trunscription 
Correspondence address: A. khwan, Dcpnrtment of Pharmacology 
and Cell Biophysics, University of Cincinnati College of Medicine, 231 
Bethesda Avenue, Cincinnati, OH 452G7-0575, USA. Fax: (I) (513) 
55s 1778. 
The full-length rat aorta u, cDNA (VSM-a,) was inserted as a 8.3 
kb Nell-Sulk fragment into the plasmid vector pf(luescript KS’ (Stra- 
lagene, Inc., La Jolla, CA) as previously described [14]. Thisconstruct 
includes the 6.8 kb coding region and does not include a poly (A)* 
tract. The cDNA template was linearixd by Sun and cRNA was 
synthesized by T3 RNA polymerase. Rubbit skeletal muscle/?-subunit 
cDNA [I61 was first cloned into a modified SlW(poly A) plasmid 
(Promegs Inc.)‘in which the &oRI site was replaced with a Kpr11 site. 
A partial digestion of the SK-BcDNA with Hir~rllll and Xbcrl followed 
by the ligation into the HindIll-Xbul site of the modified SFW(poly 
A) vector resulted in our cRNA template. The/?-subunit template was 
then linearized by Kprtl and cRNA was synthesized by SP6 RNA 
polymerase. Previously published cardiac clone% [I21 were used to 
screen 3 XZAPII library (Stratagcnc) toisolate clones which completed 
the coding frame, and these clones were used to construct a full length 
cardiac-a,. The cardiac Q, cDNA (DSHT-a,, 7.1 kb) and the skeletal 
a2 EDNA (SK-Q 3.8 kb) [9] were inserted into the Hlndlll-Xbnl and 
WI-Sac1 sites of the modified SP64 (poly A) plasmid. respectively. 
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Fig, 1, l.~ induced by VSM.~. (a) 1.., induced by VSM.u~ (trace 1); enhancement byaddition of 10 -~ M Bay K 8644 (trace 2); inhibition by addition 
of 100 #M Cd -'÷ (trace 3). l~'s were obtained by using a test pulse to 0 mV from a holding potential of -80 mV, (b) Current-voltage relationship 
oI'VSM-~t~ injected ooeyte, The open and closed circles represent the peak current amplitudes atthe indicated test potentials before and after Bay 
K 8644 treatment, respectively. 
The corresponding cRNA's were prepared as described for SK-fl. The 
cgNA's were purified by standard molecular biological procedures 
and suspended inwater at a final concentration f 1 mg per ml, 
2,2. Oocyte h~jections and electrophysiology 
Adult female Xenopus laevis frogs were purchased from Xenopus 
One (Ann Arbor, MI) and were kept under light and dark cycles of 
12 h. Injections of cRNA's were performed according to published 
procedures [17], Briefly, oocytes wereremoved surgically and treated 
with type IA collagenase (Sigma Chemical lnc,) in the following solu- 
tion (in raM): NaCl, 82,5; KCI, 2.0; MgCl2, 1.0; HEPES, 5,0 (titrated 
to pH 7.5) for 2 h at 20°C with gentle agitation, Ooeytes at stage V-VI 
were selected and injected with 40 nl of the aqueous ¢RNA solutions, 
In oocytes that expressed two subunits, 80 nl of a 1:1 mixture of 
¢RNA's were injected, Ooeytes were incubated in a solution of the 
following ¢ompositior~ (in raM): NaCl, 96,5; KCI, 2,0; CaCl:, 1.8; 
MgCl:, 1.0; HEPES. 5.0; pyruvat¢, 2.5; theophyllin¢. 0,5; penicillin, 
100 U/ml; streptomyeln, 100/.tg/ml (titrated to pH 7,4) at 20°C for 4 
to 5 days belbre lectrophysiological experiments were performed [18], 
Calcium channel activity was detected and measured by the stand- 
ard two-electrode voltage.clamp technique, usually 4 days after inje¢. 
tion. Barium was substituted for calcium, external CI- was replaced 
by  methanesulphonate, nd whole cell currents were recorded at room 
temperature in the following solution (in mM); Ba(OH)~, 40; N- 
methyl-t~.glucamine, 50; KOH, 2,0; HEPES, 5.0, and the pH was 
adjusted to 7,4 with methanesulfonic acid, The electrodes were filled 
with 3 M KCI and had resistances of 1.0 - 3,0 Mr2, Cd-'÷-insensitive 
currents were subtracted from the traces where they were mentioned, 
Data were filtered at 50 Hz and were analyzed by pCLAMP software 
package (Axon Instruments, Burlingame, CA), Diltiazem was a gift 
IYom Marion Merrell Dow, Bay K 8644 from Miles Laboratory and 
(_+)PN200-110 from Sandoz. 
3. RESULTS AND DISCUSSION 
Ba 2~ currents (In.), expressed by VSM-~t  cRNA 
alone, were enhanced by the add i t ion  o f  Bay K 8644 and 
b locked by Cd 2+ (Fig. In), Non- in jected  and SK-/~ in- 
jected oocytes d id  not  show any Bay K 8644-sensitive 
current.  Fig. 1 b shows the cur rent -vo l tage  re lat ionship 
( I -V  curve) of  peak In. o f  a VSM-0q injected oocyte.  
The max imum peak current  was obta ined  at 10 mY and 
was shifted to 0 mV after  the add i t ion  o f  Bay K 8644, 
In., expressed by VSM-~I  cRNA co- in jected with SK-f l  
cRNA,  was also enhanced by Bay K 8644 and was 
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Fig, 2. lu. induced by so.injection of VSM-0h and SK-,6, (a) I.., induced by co-injection op VSM.91 and SK-p (trace 1). Enhancement by addition 
of 10 -6 M Bay K 8644 (trace 2); suppression by 10 -~ M diltiazem (trace 3). Cd-'*-insensltlve currents were subtracted. The voltage.clamp protocol 
is the same as described inFig, 1, (b) Current-voltage relationship ofVSM-~t plus skcletalp co.injected oocyte, The open and closed circles represent 
the peak current amplitudes at the indicated test potentials before and after Bay K 8644 treatment, respectively, 
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Fig. 3. Peak current amplitudes and inactivation time constants. (a) The peak current amplitudes, induced by VSM~ and by co.injection of SK-fl. 
The hatched and closed columns are the amplitudes before and after the addition of 10 ~' M Bay K 8644., respectively. The mean __. S.E.M. are 
indicated. The number of experiments are 4 and 16 for VSM-,'h and co.injection of SK-fl, respectively. (b) Inactivation time constants (r) of VSM.,v~ 
and co-injection of SK-,& The hatched and closed columns are before and after the addition of 10 -6 M Bay K 86,44, respectively. The mean +_ S.E.M. 
are indicated. The number of experiraents are 4 and 16 for VSM-a~ and co-injection of SK-fl, respectively. 
suppressed by 10 .6 M diltiazem (Fig. 2a) and by (__) PN 
200-110 (data not shown). Fig. 2b shows the I-V curve 
of peak In, of a VSM-0q and SK-fl co-injected oocyte. 
The pattern of this 1- V curve was similar to that of the 
VSM-a~ injected oocytes. The peak la,,'s at 0 mV of 
-71_+11 nA and -357+_55 nA were enhanced by the 
addition of Bay K 8644 to levels of -165+_.56 nA and 
-429_+73 nA for VSM-gt alone (mean+_ $.E.M., n=4) 
and VSM-0h co-injected with SK-fl (mean_+ S.E.M., 
n-16), respectively (Fig. 3a). The effect of Bay K 8644 
seems to be relatively small in VSM-0h and SK-fl co- 
injected oocytes. This is due to the fact that some 
oocytes howed more than a 2-fold increase of current 
amplitude by the addition of Bay K 8644, while others 
showed a decrease of current amplitude, probably due 
to desensitization. The inactivation time constant (r) 
was not significantly changed either by co.injection of 
SK-fl or by the aXddition of Bay K 8644. t 's of 664+_78 
ms and 679±118 ms became 678_+34 ms and 695_+38 ms 
after the addition of Bay K 8644 for VSM-rn~ alone 
(mean __ S.E.M., n=4) and for ¥SM-gI co.injected with 
$K-fl (mean_+ S.E.M., n=16), respectively (Fig. 3b). 
Comparable activation and inactivation time courses 
were reported for smooth muscle cells of rat vas de- 




[40 nA [80 nA 
800 m@ 800 ms 
Fig. 4. /~ induced by DSH'r-,,~ and co.lnjectlon ofSK-s h. (a) The 
current indu~.~d by DSHT-g) (trace 1) was enhanced by 10 -6 M Bay 
K 8644 (trace 2). Cd:+-insensitive currents were subtracted. (b) The 
current induced by co.lnjectlon ofDSHT-~,~ and SK-et2 (trace !) was 
enhanced by l0 -6 M Bay K 8644 (trace 2). Cd"+-inscnsitive currents 
were subtracted. 
[19,20]. Thus, our results suggest that the calcium 
channel expressed by ~¢1 alone or by ~,1 plus fl is similar 
to a native vascular smooth muscle calcium channel. 
The Ia~ expressed by DSHT<t) (trace I, Fig. 4a) was 
similar to the expressed VSM-~). The peak la~ of -80 
nA at 0 mV was enhanced to -180 nA by the addition 
of l0 -6 M Bay K 8644 (trace 2, Fig. 4a). The average 
increase of the current amplitude by the addition of l0 -6 
M Bay K 8644 was 2.3-fold (n=4). Co-injection of 
DSHT-0h and SK-0ta in the same batch of oocytcs re- 
sulted in a 2-fold increase in peak In, compared to 
DSHT-0cj alone injected oocyte (trace I, Fig. 4b). The 
average increase of the peak current amplitude was 1.8- 
fold (n=4). Addition of l0 -6 M Bay K 8644 in DSHT-at 
and SK-0h co-injected oocytes increased the peak 
current amplitude 2.3-fold (n=4). An even larger in- 
crease was observed by co-injection of DSHT-~ and 
SK-fl, i.e. by a factor of  4.8 (n=7) (data not shown). The 
increase of peak In.. was similar to that obtained by 
co-injection of VSM-~t and SK-//. Co.injection of either 
DSHT-0h, or VSM-gt, with SK-fl and SK-ch resulted in 
still further increases in current density (data not 
shown). Analysis of the inactivation time course of these 
expressed currents did not reveal any major differences, 
compared to VSM-0q or to DSHT-g~ alone expressed 
currents. 
The fact that the expressed currents were greatly en- 
hanced by the DHP calcium agonist Bay K 8644 and 
inhibited by Cd 2+, diltiazem or (_) PN 200-1 l0 suggests 
that the currents expressed by VSM-~x~ and DSHT-ah 
are indeed of the L-type VDCC's. VSM-0~t is homolo- 
gous to DSHT-cz~ [12] which was expressed in oocytes 
here and the rabbit cardiac ~I-cDNA expressed by 
Mikami et al. [l 1]. These three clones all express Bay K 
8644-sensitive currents with similar amplitudes. Se- 
quence heterogeneity, however, does exist in two spe- 
cific regions within VSM-~I and the cardiac~t eDNA's 
[14] which may be of importance in the in rive regula- 
tion of these two types of cardiovascular VDCC's. As 
we have reported [14], the third membrane-spanning 
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domain within the last motif (IVS3) of these a:t clones 
differ; however, we have found that both forms (IVS3A 
and IVS3B) exist in rat aorta and rabbit heart. The~e 
two forms are apparently not tissue-specific as they 
have been observed in aorta, heart, and brain [15]. The 
cardiac isoform first described by Mikami et al. cor- 
responds to IVS3A while the isoforms described here 
each harbor 1VS3B. In this regard, both cardiac =~ iso- 
forms containing IVS3A or IVS3B as well as VSNI-0~t 
have been expressed and their currents appear to be 
similar. However direct comparative functional ana- 
lyses need to be carried out to determine if these iso- 
forms are functionally different. Interestingly, we have 
shown that these two distinct $3 regions arise from 
alternatively spliced adjacent exons of a single trans- 
cript [15]. A second region of diversity between the aor- 
tic and cardiac eDNA's is in a region which may play 
a role in the known distinct regulation patterns of these 
two channels, since it occurs in an area located in the 
intracellular COOH terminal region which is rich in 
potential phosphorylation sites [14]. While in vivo these 
two tissues (heart and VSM) display similar VDCC 
voltage sensitivity [20], they differ in their DHP sensi- 
tivity [20]. In addition VSM-VDCC may not be regu- 
lated by protein kinase A phosphorylation asis the case 
Ibr the VDCC in cardiac tissue [2,3,20]. In this report, 
our oocyte data yields similar currents expressed from 
aorta and heart as well as calcium antagonist pharma- 
cology. Experiments are ongoing to determine whether 
this second COOH area of diversity plays a role in 
channel regulation by other systems including phospho- 
rylation. 
It is now clear that the ~q-subunit alone does indeed 
encode a VDCC protein; the exact role of the smaller 
subunits remains to be determined. Co-injection of the 
skeletal muscle ~, [9] cRNA with the cardiac [this paper, 
11] enhanced the current amplitude but did not appear 
to change kinetics. Singer et el. [21] reported a 5-fold 
faster inactivation when cardiac g~ was co-injected with 
skeletal =_~. However, there may be a significant differ- 
ence between our ct~ and theirs, because their at ex- 
pressed current amplitude (5 nA) is considerably 
smaller than ours and that reported by Mikami et al. 
(around 80 nA). At this time, we have no other explana- 
tion for the disparate results. 
We report here a significant enhancement of VSM-~ 
and DSHT-txt currents by the co-injection of skeletal 
ft-subunit (SK-fl). Therefore, theft subunit produces the 
same effect as the ~., subunit does for cardiac ~j. Mori 
et al. [22] have shown that co-injection of SK-ft cRNA 
enhanced the current expressed by a brain-specific 
DHP-insensitive ctL eDNA, but did not change kinetics. 
This study along with the above-mentioned xperi- 
ments suggest a role for the ~-  and fl-subunit in :zt 
VDCC activity, but we emphasize that in each of these 
studies the co-expressions were with heterologous ti sue 
eDNA's. Using a homologous expression system in 
which the SK-fl was co-transfeeted with the skeletal 
muscle ~tl subunit in a mammalian cell line, we have 
shown that the SK-ft enhances SK-~j kinetics but not 
current density and dramatically increases DHP bind- 
ing [23]. In this respect, the skeletal VDCC is dissimilar 
to the cardiac and vascular smooth muscle VDCC. Un- 
derscoring the latter is the unresolved enigma that skel- 
etal at does not express in the oocyte system. In the 
present work we could not detect a significant change 
of the inactivation time constant, although we did see 
a significant enhancement of the current amplitude by 
the co-injection of SK-ft. Although there is no direct 
evidence for the existence of a ft-subunit in VSM, it is 
likely that all of the subunits do in fact exist in all tissues 
possessing VDCC activity and they may play a role in 
the regulation of the channel [24]. It is clear, though, 
that the major differences produced by homologous vs. 
heterologous expression eed to be resolved. 
The major point of the present study is that unlike 
skeletal =~ expressed in mammalian cells, the cardiac 
and aorta ctt subunits express a native-like calcium cur- 
rent in oocytes that is enhanced by ft and ~t~ subunits. 
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